Cambria Investment Management L.P. Increases Stock Holdings in Pfizer Inc. $PFE

Cambria Investment Management L.P. raised its holdings in Pfizer Inc. (NYSE:PFE) by 14.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 421,336 shares of the biopharmaceutical company’s stock after buying an additional 53,745 shares during the quarter. Cambria Investment Management L.P.’s holdings in Pfizer were worth $10,280,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $2,270,157,000. Vanguard Group Inc. raised its holdings in shares of Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after buying an additional 5,662,309 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Pfizer by 75.0% during the third quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock valued at $221,398,000 after buying an additional 3,722,531 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Pfizer by 84.9% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock valued at $183,302,000 after acquiring an additional 3,472,240 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.61 on Thursday. The stock has a market capitalization of $151.31 billion, a price-to-earnings ratio of 19.57 and a beta of 0.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The firm’s 50 day simple moving average is $26.23 and its 200-day simple moving average is $25.45. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.63 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Argus raised Pfizer to a “Buy,” giving the stock near‑term analyst momentum that can attract flows. Pfizer (NYSE:PFE) Raised to “Buy” at Argus
• Positive Sentiment: Pfizer reported progress on PF‑07328948 (kidney function) Phase 1 work — a pipeline advancement that supports longer‑term product value and upside beyond current franchises. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
• Positive Sentiment: Oncology milestones (PADCEV+Keytruda Phase 3 benefits and full FDA approval for a BRAFTOVI regimen) reshape growth prospects away from COVID‑era revenues — a material strategic positive for future revenue mix. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a tangible move toward Physical AI and factory automation that could improve throughput, quality, and costs over time. Telescope Innovations Installs Second Self-Driving Lab at Pfizer, Advancing Physical AI Deployment
• Positive Sentiment: Market commentary continues to frame Pfizer as a defensive, high‑yield option (dividend yield cited as attractive), which supports demand in risk‑off environments. The Dividend Safe Harbor: 2 Stocks to Watch (PFE)
• Positive Sentiment: Analyst/market pieces highlight improving cash generation and active portfolio renewal, reinforcing a recovery narrative that could boost multiple expansion if sustained. Pfizer’s Quiet Cash Comeback Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Consensus analyst rating remains a “Hold” per a recent roundup — a signal that while sentiment is improving, broad analyst conviction is not yet uniformly bullish. Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Hold” from Analysts
• Neutral Sentiment: Industry reports on AI in pharma manufacturing note Pfizer among large firms integrating AI — a positive trend but more structural and longer‑term than an immediate earnings driver. AI in Pharma Manufacturing Market Research 2026-2040
• Neutral Sentiment: NYSE floor events (bell‑ringing notices) are routine market color without company‑specific impact. NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Barclays initiated coverage on Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target on the stock. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Finally, Royal Bank Of Canada began coverage on shares of Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $28.05.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.